BackKinnate Biopharma Overview

Kinnate Biopharma Accounts Payable

Kinnate Biopharma's accounts payable is $2M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$2.03M
31.62% YoYΔ $-939000.00 vs prior year quarter

Peer average

Loading

Kinnate Biopharma Accounts Payable History

Loading

Kinnate Biopharma vs. peers: Accounts Payable Comparison

Loading

Kinnate Biopharma Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kinnate Biopharma (KNTE) FAQ

As of the most recent data (December 2023), KNTE shows a accounts payable of $2M. That compares with $3M in the prior-year period — down 31.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KNTE's accounts payable is now $2M (was $3M) — a 31.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kinnate Biopharma is outperforming or lagging.

Tracking KNTE's accounts payable over time shows whether Kinnate Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2M That compares with $3M in the prior-year period — down 31.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Kinnate Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2M) with ownership activity and broader fundamentals.

Kinnate Biopharma's accounts payable is $2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.